Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (11): 9-15.doi: 10.6040/j.issn.1671-7554.0.2019.358

Previous Articles     Next Articles

Risk factors of slow or no coronary flow in 182 patients with acute ST-segment elevation myocardial infarction 30 days after operation

ZHANG Wei, ZHAO Hongyan, DU Fengli, SU Guoying   

  1. Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, China
  • Published:2022-09-27

Abstract: Objective To study the risk factors of slow coronary flow/ no coronary flow(SCF/NCF)after the emergency percutaneous coronary intervention(PCI)in the patients with acute ST-segment elevation myocardial infarction 山 东 大 学 学 报 (医 学 版)57卷11期 -张伟,等.182例急性ST段抬高型心肌梗死患者术后30 d冠脉慢血流/无复流危险因素分析 \=-(STEMI), and to explore the influences of SCF/NCF on the patients 30 days after the emergency PCI. Methods A total of 334 patients with STEMI and emergency PCI were analyzed retrospectively. They were divided into the SCF/NCF group(n=182)and control group(the patients with normal coronary flow after PCI,n=152). The multivariate Logistic regression analysis was used to study the risk factors correlated with SCF/NCF after emergency PCI. The follow-up was made to explore the incidence of major adverse cardiac events(MACE), myocardial re-infarction, cardiac death, all-cause death and instent thrombosis between the two groups 30 days after PCI. Results (1) The factors with statistical differences between the two groups showed that the elevation of serum creatinine(P=0.034, OR=1.009, 95%CI: 1.001-1.017), high TIMI frame counts after pre-dilation(P=0.025, OR=1.038, 95%CI: 1.005-1.072), the high maximum stent release pressure(P=0.006, OR=1.525, 95%CI: 1.130-2.060), the high thrombus score(P=0.030, OR=1.324, 95%CI: 1.028-1.705)were the risk factors of SCF/NCF phenomenon. Non-right coronary artery as the target vessel(P<0.001, OR=0.071, 95%CI: 0.025-0.200), the high maximum pre-dilation pressure(P=0.033, OR=0.864, 95%CI: 0.755-0.989), the usage of sodium nitroprusside(P=0.006, OR=0.126, 95%CI: 0.029-0.548)and IIb/IIIa receptor antagonist(P=0.043, OR=0.438, 95%CI: 0.197-0.974)during the procedure were the protection factors of the SCF/NCF phenomenon. Among these protection factors, non-right coronary artery as the target vessel and the usage of sodium nitroprusside were dominant. (2) After 30 days of the follow-up, there were no significant differences in the incidence of MACE(14 vs 8 cases, χ2=0.753, P=0.385), cardiac death(12 vs 8 cases, χ2=0.243, P=0.622), all-cause death(12 vs 8 cases, χ2=0.243,P=0.622)and in-stent thrombosis(2 vs 0 cases, χ2=1.675, P=0.196)between the two groups. Compared with the control group, the incidence of myocardial re-infarction in SCF/NCF group was higher(6 vs 0 cases, χ2=5.087, P=0.024). (3) The causes of death were cardiac shock, in-stent thrombosis, cardiac rupture and acute heart failure. Cardiac shock is the first cause of death which accounts for 70%. Conclusion The elevation of serum creatinine, high TIMI frame count after pre-dilation, the high maximum stent release pressure and the high thrombus score are positivly correlated to the SCF/NCF phenomenon. Non-right coronary artery as the target vessel, the high maximum pre-dilation pressure, the usage of sodium nitroprusside and IIb/IIIa receptor antagonist during the procedure are negativly correlated to the SCF/NCF phenomenon. The incidence of myocardial re-infarction in the SCF/NCF group was higher than that in the control group.

Key words: Acute ST-segment elevation myocardial infarction, Emergency percutaneous coronary intervention, Slow coronary flow, No coronary flow, Risk factors, Follow-up

CLC Number: 

  • R543.3
[1] Pedersen F, Butrymovich V, Kelbaek H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI[J]. J Am Coll Cardiol, 2014, 64(20): 2101-2108.
[2] Fokkema ML, James SK, Albertsson P, et al. Population trends in percutaneous coronary intervention: 20-year results from the SCAAR(Swedish Coronary Angiography and Angioplasty Registry)[J]. J Am Coll Cardiol, 2013, 61(12): 1222-1230.
[3] 叶绍东,吴永健,李琳,等.75岁以上ST段抬高心肌梗死患者再灌注治疗进展[J].中华老年心脑血管病杂志, 2015, 17(4): 436-437.
[4] Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow[J]. Circulation, 1996, 93(5): 879-888.
[5] 顾崇怀,邓宇阳,杨晓旭,等.血栓抽吸的应用现状及进展[J].中国介入心脏病学杂志,2014, 22(7):462-464.
[6] Salinas P, Jimenez-Valero S, Moreno R, et al. Update in pharmacological management of coronary no-reflow phenomenon[J]. Cardiovasc Hematol Agents Med Chem, 2012, 10(3): 256-264.
[7] 韩雅玲,邓捷,荆全民,等.急性心肌梗死急诊介入治疗无再流发生的独立预测因素及对长期预后的影响[J].中华心血管病杂志,2006, 34(6): 483-486. HAN Yaling, DNEG Jie, JING Quanmin, et al. Post primary percutaneous coronary intervention no-reflow in patients with acute myocardial infarction: contributing factors and long-term prognostic impact[J]. Chin J Cardiol, 2006, 34(6): 483-486.
[8] Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarc-tion[J]. Indian Heart J, 2016, 68(4): 539-551.
[9] 戴敬,吕树铮,宋现涛,等.介入术后无复流现象的研究进展[J].心肺血管病杂志, 2014, 33(1): 133-135.
[10] 赵林,张宇晨,郭成军,等.入院肾小球滤过率对ST段抬高心肌梗死患者急诊介入治疗术后心肌灌注及预后的影响[J]. 中国介入心脏病学杂志,2012,20(5): 262-266. ZHAO Lin, ZHANG Yuchen, GUO Chengjun, et al. Effect of admission estimated glomerular filtration rate on myocardial perfusion and prognosis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention[J]. Chin J Intervent Cardiol, 2012, 20(5): 262-266.
[11] 王祥. 隐性肾功能不全对冠脉病变及临床预后的影响分析[D].长春:吉林大学,2014.
[12] 李凤丽,任法鑫,董梅.肾功能不全与心肌无复流关系的研究进展[J].医学综述, 2017, 23(6): 3245-3249. LI Fengli, REN Faxin, DONG Mei. Research progress of relationship between renal insufficiency and myocardial no-refolw[J]. Medical Recapitulate, 2017, 23(6): 3245-3249.
[13] Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial[J]. J Am Coll Cardiol, 2006, 47(3): 522-528.
[14] Kaul S. The “no reflow” phenomenon following acute myocardial infarction: mechanisms and treatment options[J]. J Cardiol, 2014, 64(2): 77-85.
[15] Wong DT, Puri R, Richardson JD, et al. Myocardial 'no-reflow' -diagnosis, pathophysiology and treatment[J]. Int J Cardiol, 2013, 167(5): 1798-1806.
[16] Uyarel H, Ergelen M, Cicek G, et al. Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction[J]. Coronary Artery Dis, 2011, 22(3): 138-144.
[17] Azab B, Torbey E, Hatoum H, et al. Usefulness of red cell distribution width in predicting all-cause long-term mortality after non-ST-elevation myocardial infarction[J]. Cardiology, 2011, 119(2): 72-80.
[18] Campagna JA, Carter C. Clinical relevance of the Bezold-Jarisch reflex[J]. Anesthesiology, 2003, 98(5): 1250-1260.
[19] Esente P, Giambartolomei A, Gensini GG, et al. Coronary reperfusion and Bezold-Jarisch reflex(bradycardia and hypotension)[J]. Am J Cardiol, 1983, 52(3): 221-224.
[20] 陈泽江,黄修献,李昭祺.替罗非班联合硝普钠对急诊PCI术中无复流现象的疗效观察[J].湖南师范大学学报(医学版), 2018, 15(6): 123-126. CHEN Zejiang, HUANG Xiuxian, LI Zhaoqi. Efficacy of tirofiban combined with sodium nitroprusside in the treatment of no-reflow phenomenon during emergency PCI[J]. J Hunan Normal Univ(Med Sci), 2018, 15(6): 123-126.
[21] Klein LW, Kern MJ, Berger P, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon on the cardiac catheterization laboratory[J]. Cather Cardiovasc Interv, 2003, 60(2): 194-201.
[22] Muller O, Trana C, Eeckhout E. Myocardial no-reflow treatment[J]. Curr Vasc Pharmacol, 2013, 11(2): 278-285.
[23] Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction[J]. Indian Heart J, 2016, 68(4): 539-551.
[24] 任晖,黄立勋,庄贵华,等.急性心肌梗死急诊经皮冠状动脉介入治疗患者院内死亡因素分析[J].心脏杂志,2014,26(6): 662-665. REN Hui, HUANG Lixun, ZHUANG Guihua, et al. Analysis of in-hospital death in acute myocardial infarction patients treated with emergency percutaneous coronary intervention[J].Chin Heart J, 2014, 26(6): 662-665.
[25] Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J]. J Am Coll Cardiol, 2010, 55(21): 2383-2389.
[1] LIU Huijun, WU Zhaoting, WANG Yuli, XU Mingyang, LIU Xiao, KANG Yan, WANG Hongmei. Risk factors and early intervention for postpartum hemorrhage caused by lower uterine segment atony [J]. Journal of Shandong University (Health Sciences), 2026, 64(5): 61-66.
[2] PANG Jinhong, SU Ping, QIAO Junpeng, CHEN Qiaoqiao, CHEN Xueyu, ZHAO Yingying, SHI Jie, SUN Xiaoru, LI Qiuchun, HE Ruiyan, FAN Yiou, CHI Weiwei. Association between modifiable cardiovascular risk factors clustering patterns and stroke in the elderly population [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 11-19.
[3] ZHANG Zheng, WANG Jianwei, YANG Yujuan, ZHANG Yu, SONG Xicheng. Immunoglobulin E changes and risk factors in asthma children between 2008 and 2019 [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 32-36.
[4] LI Jing, HAO Panpan. Association between the heart rate variation and the prognosis in patients with acute heart failure at hospital admission and discharge [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 75-82.
[5] CHENG Zhenyu, LAI Qingguo, WU Mengtao. Advances in influencing factors of in-stent restenosis after iliofemoral vein stenting [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 112-117.
[6] CHENG Yueqi, WANG Fei, YU Lixiang, ZHENG Chao, YU Zhigang. Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 17-24.
[7] WANG Zheyu, XU Yi, ZHAO Changbo, YANG Shuofei, NI Qihong, CHEN Jiaquan, WANG Weilun, LI Yinan, GUO Xiangjiang, YE Meng, ZHANG Lan, XUE Guanhua. Risk factors and management for iliac branch occlusion after endovascular abdominal aortic aneurysm repair [J]. Journal of Shandong University (Health Sciences), 2024, 62(9): 101-107.
[8] LI Jian, SUN Yun. Risk factors for death within 2 years in new maintenance haemodialysis patients [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 48-53.
[9] SONG Han, WANG Zhenhua, WEI Duoliang, XU Kai, LI Bowen, ZHAO Xin. Impacts of preoperative MELD grades on the postoperative early outcomes of 304 acute Standford type A aortic dissection patients [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 31-36.
[10] ZHANG Meng, MA Wei. Trend and disease burden of human immunodeficiency virus/acquired immunodeficiency syndrome in China from 1990 to 2019 [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 84-89.
[11] MU Yanxi, LI Jinzhou, CHEN Kang, LIANG Hongying, YAO Yalong, WANG Wenjie, CHEN Xiao. Risk factors of pulmonary complications after radical gastrectomy in 443 cases [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 37-41.
[12] SHAO Changxiu, HE Qingqing, ZHUANG Xiaoxuan, LI Xiaolei, ZHOU Peng, YUE Tao, GAO Yuan, XU Jing, LI Chenyu, GUO Haonan, ZHUANG Dayong. Patterns and risk factors of cervical lymph node metastasis in 934 cases of papillary thyroid microcarcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(2): 57-64.
[13] CI Qianqian, WU Shengying, WAN Qiuhua, MA Yunrong, ZHAO Jianwen, ZHANG Jian. Analysis of prenatal screening and diagnostic methods in 10,265 cases of advanced maternal age [J]. Journal of Shandong University (Health Sciences), 2023, 61(1): 51-57.
[14] YAO Xue, LU Ranran, SUN Shuling, GAO Cuiping, XIAO Ru, WANG Shuhui. Establishment of a risk prediction scoring model for nosocomial infection in rheumatic heart disease patients after valve replacement surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 90-96.
[15] KONG Xinxin, SUN Shuzhen, LI Qian, CHEN Yuan, ZHOU Aihua, WANG Li, YAO Xiujun. Analysis of 7 cases of anti-H factor antibody-positive hemolytic uremic syndrome [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 82-86.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!